Long Intergenic Non-Coding RNAs of Human Chromosome 18: Focus on Cancers

• Published in: Biomedicines Vol. 12; no. 3; p. 544
• Main Authors: Ershov, Pavel V, Yablokov, Evgeniy O, Mezentsev, Yuri V, Ivanov, Alexis S
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28-02-2024; MDPI
• Subjects: Analysis; Bladder cancer; Brain cancer; Breast cancer; Cancer; cancers; Carcinogenesis; Chromosome 18; Chromosomes; Gene expression; Gene set enrichment analysis; Genes; Genetic aspects; Genomic analysis; Head & neck cancer; Ipilimumab; Kinases; Liver cancer; long-intergenic non-coding RNA; MicroRNA; miRNA; Molecular biology; Non-coding RNA; Oncology, Experimental; open-reading frame; Prostate; Proteins; Review; RNA–RNA interactions; Thyroid gland; Transcriptomics; Tumors; transcriptomic signatures; RNA–RNA interactions; non-coding RNA; RNA–protein interactions; long-intergenic non-coding RNA; cancers; open-reading frame; chromosome 18
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12030544

Malignant neoplasms are characterized by high molecular heterogeneity due to multilevel deregulation of gene expression and cellular functions. It is known that non-coding RNAs, including long intergenic non-coding RNAs (lincRNAs), can play significant roles in cancer biology. The current review focuses on a systematical analysis of genomic, transcriptomic, epigenomic, interactomic, and literature data on 65 lincRNAs of human chromosome 18 in the context of pan-cancer studies. The entire group of lincRNAs can be conditionally divided into 4 subgroups depending on experimental evidence on direct or indirect involvement in cancers and the biological associations with cancers, which we found during the data-mining process: the most studied (5 lincRNAs), moderately or poorly studied (11 lincRNAs), and understudied (31 lincRNAs). For the remaining 18 lincRNAs, data for analysis were fragmentary or missing. Among the key findings were the following: Of the lincRNAs of human chromosome 18, 40% have tissue-specific expression patterns, 22% of lincRNAs are known to have gene fusions, 40% of lincRNAs are prone to gene amplifications and/or deletions in cancers at a frequency greater than 3%, and 23% of lincRNAs are differentially expressed across cancer types, whereas 7% have subtype-specific expression patterns. LincRNAs' interactomes consist of 'master' microRNAs and 47 proteins (including cancer-associated proteins and microRNAs) that can interact with 3 or more lincRNAs. Functional enrichment analysis of a set of highly co-expressed genes retrieved for 17 lincRNAs in different cancer types indicated the potential associations of these lincRNAs with cellular signaling pathways. Six lincRNAs encoded small open-reading frame (smORF) proteins with emerging roles in cancers, and microRNAs as well as proteins with known functions in molecular carcinogenesis can bind to coding regions of smORFs. We identified seven transcriptomic signatures with potential prognostic value, consisting of two to seven different lincRNAs only. Taken together, the literature, biomedical, and molecular biology data analyzed indicated that only five of all lincRNAs of human chromosome 18 are cancer-associated, while eleven other lincRNAs have the tendency to be associated with cancers.